Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 15:7:1291-9.
doi: 10.2147/OTT.S49430. eCollection 2014.

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

Daniel C McFarland  1 , Krzysztof J Misiukiewicz  2
Affiliations
Free PMC article
Review

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

Daniel C McFarland et al. Onco Targets Ther. .
Free PMC article

Abstract

Recent Phase III data presented at the American Society of Clinical Oncology (ASCO) 2013 annual conference by Brose et al led to the US Food and Drug Administration (FDA) approval of sorafenib for the treatment of well-differentiated radioactive iodine-resistant metastatic thyroid cancer. This is the second drug in 40 years to be FDA approved for this indication. Recent reviews and a meta-analysis reveal a modest ability to induce a partial remission but substantial ability to halt disease progression. Given the significant activating mutations present in thyroid cancer, many of which are inhibited by sorafenib, the next logical approach may be to combine targeted rational therapies if permitted by collective toxicity profiles. This systematic review aims to summarize the recent Phase II/III data leading to the FDA approval of sorafenib for radioactive iodine therapy differentiated thyroid cancer and highlights recent novel combination therapy trials.

Keywords: RAI DTC; novel thyroid cancer treatment; targeted therapy; tyrosine kinase inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brose MS, Nutting C, Jarzab B, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the Phase III DECISION trial. J Clin Oncol. 2013;31(suppl; abstr 4a)
    1. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastasis from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–2899. - PubMed
    1. Nikiforov Y, Nikiforova M. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569–580. - PubMed
    1. SEER Stat Fact Sheets: Thyroid Cancer [webpage on the Internet] National Cancer Institute; 2011. Available from: http://seer.cancer.gov/statfacts/html/thyro.html#incidence-mortality. Accessed.
    1. Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63:960–967. - PubMed

LinkOut - more resources